SLC2A1 and epilepsy: The clinical targeted next generation epilepsy panels include PDE-ALDH7A1, PNPO and GLUT1 deficiencies and dystonia panels include TH, GTPCH, GLUT1, SR and dopamine transporter deficiencies.